Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, postponed its IPO on Monday. It had filed to raise $55 million by offering 5.0 million shares at a price range of $10 to $12, for a proposed post-IPO market value of $141 million.
The Jerusalem, Israel-based company was founded in 2009 and had planned to list on the Nasdaq under the symbol ENTX. Oppenheimer & Co. was set to be the sole bookrunner on the deal.
